Genocea competitors

Hamza Suri is a President & CEO at AnaptysBio Inc.

Jeff Albers is the chief executive officer of [Blueprint Medicines](https://www.crunchbase.com/organization/blueprint-medicines), a company engaged in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets. He was previously the president of Algeta. Prior to Algeta, he served at Genzyme, where he spent seven years in senior commercial and corporate development positions. Before joining Genzyme, he spent five years as an Attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo. He also has prior experience as a sales representative for Pfizer. Albers holds a bachelor’s degree in marketing from Indiana University and an MBA from Georgetown University.

Michael Morrissey is a President/CEO at EXELIXIS, INC.; Board Member at EXELIXIS, INC.; and Board Member at XW LABORATORIES INC and is based in Danville, California. He has experience at Schering AG and has worked as VP:Discovery Research at Berlex Biosciences; Senior Scientist at Novartis; and Senior VP:Discovery at EXELIXIS, INC.. Michael studied at Harvard University and University of Wisconsin Oshkosh.

Adelene Perkins serves as Infinity’s chief executive officer and Infinity’s chair, a position she has held since 2012. She was named chief executive officer and elected to the Board of Directors in 2009. Before serving as CEO, Ms. Perkins served as Infinity’s President, a position she held since 2008. Ms. Perkins joined Infinity in June 2002 as executive vice president and chief business officer. Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as vice president of business and corporate development and an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, from 1992-1999, she was at Genetics Institute, now a unit of Pfizer, where she was vice president of emerging businesses and the co-founder and general manager of the DiscoverEase™ business unit. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University. She joined Genetics Institute in corporate and business development where she led corporate and product strategy initiatives. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry. Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. In addition to chairing the Infinity (NASDAQ: INFI) Board, she is on the Boards of Bruker Corporation (NASDAQ: BRKR), Massachusetts General Hospital, BIO (Biotechnology Industry Organization), the Massachusetts Biotechnology Council, and is the vice chairman of the Board of Project Hope. She is a past member of the Boards of Padlock Therapeutics, prior to its acquisition by Bristol-Myers Squibb, and the Massachusetts Life Science Center.

Mr. George B. Kauffman is a Chairman Chief Executive Officer;Chief Investment Officier at RIGEL PHARMACEUTICALS INC and is based in United States.

Rick Winningham has served as a member of our Board of Directors since May 2010. Since 2001, he has served as the Chief Executive Officer and a member of the Board of Directors of Theravance, Inc., a biopharmaceutical company, and in April 2010, he was appointed Chairman of the Board of Directors. From 1997 to 2001, he served as President of Bristol-Myers Squibb Oncology/Immunology/Oncology Therapeutics Network and, from 2000 to 2001, as President of Global Marketing. He is a member of the board of directors of the California Healthcare Institute (CHI) and is also a member of the External Advisory Board for the College of Business and Administration and Business Hall of Fame at Southern Illinois University.Rick Winningham holds an M.B.A. from Texas Christian University and a B.S. from Southern Illinois University.

Ron Squarer serves as Chairman and Executive Advisor at ADC Therapeutics SA (NYSE: ADCT) and directly supported the May 2020 company IPO. Mr. Squarer served as Chief Executive Officer and a member of the Array Biopharma Board of Directors from April 2012 through August 2019 when Pfizer Inc. acquired the company for $11.8 billion following the successful launch of the cancer treatments Braftovi® and Mektovi®. During his tenure, the company’s valuation grew ~40-fold through execution across research, development, and commercialization focused in the Oncology area. Array Biopharma’s research team is recognized for having invented Vitrakvi®/larotrectinib/TRK, Koselugo®/selumetinib/MEK, Tukysa®/tucatinib/HER2, ipatasertib/AKT, selpercatinib/RET, and MRTX849/KRAS-G12C among other molecules. Mr. Squarer has extensive commercial, development, research prioritization, and executive leadership expertise from a career spanning more than two decades in the biopharmaceutical industry. Before joining Array, Mr. Squarer held positions of increasing responsibility with Hospira, Inc., a global pharmaceutical and medical device company. In his last role there, as Senior Vice President and Chief Commercial Officer, he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, where he served as Senior Vice President, Global Corporate and Business Development when Mayne was sold to Hospira in 2007 for over $2 billion. Before Mayne Pharma, Mr. Squarer held leadership roles at both Pfizer, Inc. (including in Oncology), and SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe and currently serves as a member of the Board of Directors of Deciphera Inc. (NASDAQ: DCPH) and Travere Therapeutics Inc. (NASDAQ: TVTX) Mr. Squarer earned an MBA from the Kellogg School of Management, Northwestern University, and a bachelor’s degree in biochemistry from the University of California, Berkeley.